Edity Therapeutics
Using Human Immune Cells to Deliver Therapeutic Proteins
Company Overview
Snapshot
Founded in October 2019 by Eyal Kolka, Michal Golan Mashiach, and Yoav Manaster, Edity Therapeutics operates with 11–50 employees. The company has raised $13.63 million across 3 funding rounds from 7 investors. In January 2024, Edity Therapeutics entered into a strategic collaboration with Dr. Reddy's Laboratories to advance its novel cell therapy approach.
Business overview
Edity Therapeutics is a Health Tech & Life Sciences company developing a platform that leverages the immune system to deliver therapeutic proteins directly to the cytoplasm of target cells. This technology aims to reprogram cells and tissue to restore health by changing the course of disease at an intracellular level through mechanisms such as protein replacement, target modulation, genetic correction, and protein gain of function. The company is currently focused on indications in oncology and genetic disease, with plans for regeneration and longevity programs, operating within the Drugs Discovery & Development sector.
Strategic signal
In January 2024, Edity Therapeutics announced a strategic collaboration with Dr. Reddy's Laboratories to advance its novel cell therapy approach. This partnership signals significant external validation of Edity's proprietary delivery platform and its potential to impact the pharmaceutical industry, particularly in developing new therapeutic proteins for various diseases. For investors, this collaboration indicates a strong move towards commercialization and further development of its core technology.
Company Intelligence Q&A
- What was a significant recent strategic collaboration for Edity Therapeutics?
- In January 2024, Edity Therapeutics entered into a strategic collaboration with Dr. Reddy's Laboratories to advance its novel cell therapy approach, utilizing Edity's proprietary delivery platform.
- When was Edity Therapeutics founded and by whom?
- Edity Therapeutics was founded in October 2019 by Eyal Kolka, Michal Golan Mashiach, and Yoav Manaster.
- What is Edity Therapeutics' primary focus in drug development?
- Edity Therapeutics is developing a platform that harnesses the immune system to deliver therapeutic proteins directly to target cells, aiming to reprogram cells and tissue for health. The company is working on indications in oncology and genetic disease, with future programs in regeneration and longevity.
- Which investors participated in Edity Therapeutics' October 2023 funding round?
- In October 2023, Edity Therapeutics received funding from investors including OurCrowd.
- Which investors participated in Edity Therapeutics' September 2021 funding round?
- In September 2021, Edity Therapeutics received funding from investors including.